Примери за използване на Gnrh agonist на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Not recommended with a GnRH agonist protocol.
There are limited data on the use of Elonva in combination with a GnRH agonist.
Hormonal treatments with GnRH agonists(like Lupron).
The Bemfola and GnRH agonist are then both given until your follicles develop as desired.
Therefore, the use of Elonva is not recommended in combination with a GnRH agonist(see also section 4.2).
Less commonly, a GnRH agonist can be used to stimulate ovulation instead of the usual hCG trigger shot during an IUI cycle.
This test assesses estradiol(E2)changes on the third day after applying GnRH agonist on the second day of the menstrual cycle.
If a GnRH agonist has been given, higher doses of Puregon may be needed to achieve a response.
A reduction in glucose tolerance has been observed in men who have had orchiectomy orwho have been treated with a GnRH agonist.
Azagly-nafarelin, a GnRH agonist, has biphasic effects on the pituitary gland when administered continuously.
Puregon can be given either alone, or, to prevent premature luteinisation, in combination with a GnRH agonist or antagonist.
Lupron, a GnRH agonist, is one of the best known and most hated of IVF treatment injectable fertility drugs.
Decreased bone density has been reported in the medical literature in men who have had orchiectomy orwho have been treated with a GnRH agonist.
If a GnRH agonist(a medicine used to prevent early ovulation) has been given, higher doses of Puregon may be needed.
As a result a rapid, profound, reversible suppression of endogenous gonadotrophins occurs,without initial stimulation as induced by GnRH agonists.
When using a GnRH agonist, a higher total treatment dose of Puregon may be required to achieve an adequate follicular response.
Changes in bone density Decreased bone density has been reported in the medical literature in men who have had orchiectomy orwho have been treated with a GnRH agonist.
GnRH agonists usually lead to endometriosis remission during treatment and sometimes for months or years afterward.
Add-back hormone therapy, which typically consists of a synthetic progesterone(progestin) administered alone or in combination with a low-dose estrogen,is typically prescribed along with GnRH agonists to alleviate these side effects.
The GnRH agonist, deslorelin, acts by suppressing the function of the pituitary-gonadal axis when applied in a low, continuous dose.
In clinical trials investigating more than 1000 newborns it has been demonstrated that the incidence of congenital malformations in children born after COH treatment using Orgalutran is comparable with that reported after COH treatment using a GnRH agonist.
The use of Elonva in combination with a GnRH agonist(another medicine to prevent your ovary from releasing an egg too early) is not recommended.
In clinical studies investigating more than 1,000 newborns it has been demonstrated that the incidence of congenital malformations in children born after COH treatment using Orgalutran is comparable with that reported after COH treatment using a GnRH agonist.
Unlike GnRH agonists, GnRH antagonists do not induce a LH surge with subsequent testosterone surge/tumour stimulation and potential symptomatic flare after the initiation of treatment.
In clinical studies, one hour after injection, the incidence of at least once a moderate or severe local skin reaction per treatment cycle, as reported by patients, was 12% in Orgalutran treated patients and25% in patients treated subcutaneously with a GnRH agonist.
If you are also receiving treatment with a GnRH agonist(a medicine that acts like a hormone called Gonadotrophin Releasing Hormone, GnRH), Menopur should be started approximately 2 weeks after the start of the GnRH agonist therapy.
In clinical studies, one hour after injection, the incidence of at least once a moderate or severe local skin reaction per treatment cycle, as reported by patients, was 12% in Orgalutran treated patients and25% in patients treated subcutaneously with a GnRH agonist.
Orgalutran was compared with buserelin, leuprorelin,and triptorelin(GnRH agonists: another group of medicines used to prevent premature ovulation, which work by stimulating the receptor for GnRH to such an extent that the body stops making LH).
In controlled studies of Orgalutran with FSH,using a long protocol of GnRH agonist as a reference, treatment with the Orgalutran regimen resulted in a faster follicular growth during the first days of stimulation but the final cohort of growing follicles was slightly smaller and produced on average less oestradiol.
In controlled studies of Orgalutran,using a long protocol of GnRH agonist as a reference, treatment with the Orgalutran regimen resulted in a faster follicular growth during the first days of stimulation but the final cohort of growing follicles was slightly smaller and produced on average less oestradiol.